Whitepaper - Pharmaceutical Executive



2014 US Trends in Aggregate Spend and Transparency

April 18, 2014

Find out how manufacturers are adapting to Sunshine and the increase in global transparency, and what U.S. physicians think about the new regulation, in Cegedim’s 5th annual industry survey.

Enabling Holistic, Strategic Risk-Based Monitoring

April 11, 2014

This white paper examines the current state of risk-based monitoring. It reviews the limitations of current eClinical technology to support monitoring best practices, and why sponsors and CROs are shifting to comprehensive, real-time analytics to conduct a strategic risk-based monitoring program.

Best Practices in Digital Journal App Advertising

April 1, 2014

Tablets are revolutionizing the way healthcare professionals access clinical content. Learn how digital journals are leveraging interactive learning to enhance reader experience and usage. Discover the unique advantages of journal in-app advertising. Explore practical tips and case examples that maximize the impact of multimedia content and create meaningful brand experiences.

When Marketing for Adherence, Don’t Ignore the Silent Majority

April 1, 2014

The importance of adherence is well recognized by industry, government, and a variety of healthcare experts. But motivating adherence is not always well understood. In this paper, inVentiv Health’s PMG shows how behavioral science, combined with online data and scientific evidence, can facilitate the behavior changes that can make a real difference to individual and public health.

Finding Feasibility: A Digital Discussion on Identifying Viable Products

March 25, 2014

Ken Phelps, Camargo Pharmaceutical Services president and CEO, sat down withPharmaceutical Executive to discuss identifying and pursuing the most viable products for development. In this Q&A session, Phelps shares his insight on how generics companies are overcoming the patent cliff and how Camargo goes about assessing the feasibility of drug candidates. He explains the success factors in identifying viable products that the Camargo team evaluates and how that evaluation can set the cornerstone of a time- and cost-effective development plan via the 505(b)(2) pathway. This interview will give you an inside look at how pharmaceutical companies and product developers are best preparing for the future and how you can too.

Market Profile of U.S. Oncologists

March 7, 2014

This OneKey report provides actionable insights on oncologists, an important group of specialists treating America's second deadliest disease category. Use it to formulate better marketing and engagement strategies with oncologists.

Global Digital Security: The Human Element

February 28, 2014

The health care industry will be among the most susceptible industries to publicly disclosed and widely scrutinized data breaches. Learn how to protect private data by developing a comprehensive strategy for preventing, preparing and responding to attacks.

Forecasting Trial Enrollment: More Data, Better Analytics, Greater Predictability

January 28, 2014

Using a data-driven approach to determining trial feasibility can eliminate guesswork and specify with a high degree of confidence exactly how long it will take to fulfill enrollment timelines.

Reprints at the Dawn of the 'Sunshine Act'

January 28, 2014

Medical journal article reprints provide health care professionals credible clinical evidence that a product works. Read about the new reprint regulations emerging from the Sunshine Act. Learn about newer ePrint formats and discover new distribution channels to get the right article to the right prescriber at the right time.


Click here